IMMUNOTERAPIYA YORDAMIDA YANGI PAYDO BO‘LADIGAN O‘SMALAR VA BOSHQA OG‘IR KASALLIKLARGA QARSHI KURASH
Keywords:
immunoterapiya; T‑limfotsit; CTLA‑4; PD‑1/PD‑L1; o‘sma mikro‑muhiti; kombinatsiyalangan terapiya; xotira T‑hujayralari; sitokinlar (IL‑2, IL‑7, IL‑15)Abstract
Immun tizimining o‘zgargan yoki anomaliyaga uchragan hujayralarni aniqlash va yo‘q qilish qobiliyati turli turdagi saraton rivojlanishiga to‘sqinlik qilishi mumkin. Immun tizimdan neoplastik bo‘lmagan holatni saqlash va saratonga qarshi immunoterapiyani rivojlantirish vositasi sifatida foydalanish g‘oyasi keng o‘rganilgan. Biroq ma’lum vaziyatlarda immun tizim onkogen jarayonni kuchaytirishi ham mumkin. Mezbonning immun javobi o‘smalarning o‘sishi va tarqalishini to‘xtata olmagani shuni ko‘rsatadiki, immunologik va noimmunologik omillar birgalikda o‘sma hosil bo‘lishiga ta’sir qiladi. Shuning uchun mezbon immun tizimi va o‘sma o‘rtasidagi murakkab o‘zaro ta’sirlarni o‘rganuvchi o‘sma immunologiyasining jihatlarini chuqur anglash nihoyatda muhim.
References
1. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer. 2012;12(4):252–264.
2. Topalian S.L., Hodi F.S., Brahmer J.R., va boshq. Safety, activity, and immune correlates of anti–PD‑1 antibody in cancer. New England Journal of Medicine. 2012;366(26):2443–2454.
3. Hodi F.S., O’Day S.J., McDermott D.F., va boshq. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine. 2010;363(8):711–723.
4. Chen D.S., Mellman I. Oncology meets immunology: the cancer‑immunity cycle. Immunity. 2013;39(1):1–10.
5. Ribas A., Wolchok J.D. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355.
6. Waldman A.D., Fritz J.M., Lenardo M.J. A guide to cancer immunotherapy: from T cell biology to clinical benefit. Nature Reviews Immunology. 2020;20(11):651–668.
7. June C.H., O’Connor R.S., Kawalekar O.U., Ghassemi S., Milone M.C. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365.
